AGE-RELATED MACULAR DEGENERATION

This early-stage study is testing the safety of a new treatment for advanced dry age-related macular degeneration (AMD), a leading cause of vision loss in older adults. Doctors are transplanting retinal cells grown from human embryonic stem cells into the eyes of about 24 patient…

This early-stage study is testing a one-time gene therapy injection for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if this single treatment can safely reduce the need for the frequent anti-VEGF injections patients cu…

This is an early-stage safety study testing a new gene therapy called KH658 for people with 'wet' age-related macular degeneration (AMD), a leading cause of vision loss. The therapy is designed as a one-time injection into the eye to deliver a gene that helps block the abnormal b…

This study is testing the safety and early effectiveness of an experimental drug called Kamuvudine-8 (K8) for people with geographic atrophy, an advanced form of age-related macular degeneration that causes permanent vision loss. Up to 30 participants will receive injections of t…

This study is a long-term safety check for 18 patients who previously received an experimental gene therapy called RetinoStat for wet age-related macular degeneration, a leading cause of vision loss. The main goal is to monitor these patients for any long-term side effects after …

This early-stage study is testing the safety of a new gene therapy called KH631 for people with 'wet' age-related macular degeneration (AMD), a leading cause of vision loss. The therapy is designed as a one-time injection into the eye to help the body block a protein that causes …

This study is testing whether artificial intelligence (AI) software can help eye doctors diagnose diseases from retinal photographs. Ten eye doctors and residents will review the same set of eye scan images, first without and then with the AI's help. Researchers will measure if u…

This study is testing a new automated eye-tracking system called AVIGA. It aims to help doctors monitor vision changes in people with wet age-related macular degeneration (AMD) more easily and objectively. The system tracks where a person looks to detect problems with central vis…

This study is testing a new, advanced eye scanner that takes extremely detailed 3D pictures of the retina. The goal is to see if this technology can help doctors detect and understand age-related macular degeneration (AMD) earlier and better. The study will involve 50 people, som…

This study aims to better understand how intermediate age-related macular degeneration (AMD) worsens over time. Researchers will follow 400 participants with early-stage AMD for about 3 years, tracking how quickly their vision changes and measuring specific eye structures. The go…

This study is testing a surprising idea: that a specific type of blood vessel growth in the eye might actually help protect vision in people with age-related macular degeneration (AMD), rather than harm it. Researchers are closely watching 73 participants with this specific vesse…

This study continues tracking the eye health of people who participated in two previous major eye research projects. Researchers follow participants annually for five years to better understand how age-related macular degeneration and cataracts naturally progress over time. The s…

This study aims to build a large database of detailed eye scans from 1,000 people with intermediate age-related macular degeneration (AMD). Researchers will analyze these scans to identify early signs that predict which patients are most likely to progress to more severe vision l…

This study follows 57 people with age-related macular degeneration (AMD) for five more years to understand how their eyes adjust to darkness over time. Participants who completed an earlier study will have regular eye exams and vision tests. The goal is to learn how changes in ni…

This 5-year study aims to understand if measuring how quickly eyes adjust to darkness can help identify and monitor early to intermediate stages of dry age-related macular degeneration (AMD). Researchers will follow about 240 participants, some with varying stages of AMD and some…